N/A
Manufactured by BioMarin Pharmaceutical Inc.
8,360 FDA adverse event reports analyzed
Last updated: 2026-04-15
SAPROPTERIN DIHYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by BioMarin Pharmaceutical Inc.. The most commonly reported adverse reactions for SAPROPTERIN DIHYDROCHLORIDE include DRUG INEFFECTIVE, HEADACHE, THERAPY NON-RESPONDER, VOMITING, MATERNAL EXPOSURE DURING PREGNANCY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for SAPROPTERIN DIHYDROCHLORIDE.
Out of 6,122 classified reports for SAPROPTERIN DIHYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 8,360 FDA FAERS reports that mention SAPROPTERIN DIHYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, HEADACHE, THERAPY NON-RESPONDER, VOMITING, MATERNAL EXPOSURE DURING PREGNANCY, DIARRHOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list BioMarin Pharmaceutical Inc. in connection with SAPROPTERIN DIHYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.